Advertisement
Screener

CAPRICOR THERAPEUTICS, INC. (CAPR) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

CAPRICOR THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

CAPRICOR THERAPEUTICS, INC. (CAPR) had Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.39 per share as of 2020-02-12, per its 10-K filed 2022-03-11.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2022-03-11

  • CAPRICOR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2014-03-31 was $12.00.
  • CAPRICOR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.00.
  • CAPRICOR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2013 was $0.31.
  • CAPRICOR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
  • CAPRICOR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2011 was $0.68.
Period endShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month
2020-02-12$1.39
10-K · filed 2022-03-11
2014-03-31$12.00
10-Q · filed 2014-05-15
2013-12-31$0.31
10-K · filed 2014-03-31
2013-09-30$0.00
10-Q · filed 2013-11-14
2013-06-30$0.00
10-Q · filed 2013-08-14
2013-03-31$0.00
10-Q · filed 2013-06-21
2012-12-31$0.00
10-K · filed 2013-06-21
2012-09-30$0.00
10-Q · filed 2013-06-21
2011-12-31$0.68
10-K · filed 2013-06-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63